Expression and clinical significance of MHC Ⅱ in medullary thyroid carcinoma
10.3760/cma.j.cn113855-20191007-00585
- VernacularTitle:甲状腺髓样癌中主要组织相容性复合体Ⅱ的表达及其意义
- Author:
Xiukun HOU
1
;
Xiangqian ZHENG
;
Dapeng LI
;
Jingzhu ZHAO
;
Ming GAO
Author Information
1. 天津医科大学肿瘤医院甲状腺颈部肿瘤科 国家肿瘤临床医学研究中心，天津市"肿瘤防治"重点实验室，天津市恶性肿瘤临床医学研究中心 300060
- From:
Chinese Journal of General Surgery
2020;35(6):480-483
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To examine the expression of MHC class Ⅱ in medullary thyroid carcinoma(MTC) and analyze its clinical significance.Methods:98 MTC patients treated at Tumor Hospital of Tianjin Medical University from Jan 2010 to Dec 2018 were included for the study. Immunohistochemistry was used to detect the expression of MHC class Ⅱ molecule .Results:The high expression of MHC class Ⅱ was not correlated with age (χ 2=0.900, P=0.410), multifocal (χ 2=0.295, P=0.672), bilateral (χ 2=2.957, P=0.127), T stage (χ 2=0.554, P=0.457), but correlated with gender (χ 2=5.227, P=0.025), preoperative calcitonin level (χ 2=6.663, P=0.019), lymph node metastasis (χ 2=21.651, P<0.001) and AJCC stage (χ 2=19.522, P<0.001). Overall survival rate of patients with high expression of MHC class Ⅱ was 97.4%.It was significantly higher than that of patients with low expression 66.1% ( P=0.016 3). COX regression model showed that age >55 years old ( HR=4.129, P=0.009), T stage ( HR=3.265, P=0.024) were independent risk factors for the prognosis of MTC patients. High expression of MHC class Ⅱ molecules ( HR=0.103, P=0.030) was a protective factor for the prognosis of MTC patients. Conclusion:The MTC patients with high expression of MHC class Ⅱ have a better prognosis.
